News MSD trims outlook as it aims to shave $3bn off costs MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.
News MSD has gauged its financial hit from Trump tariffs MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.
News BMS bags a double-quick colorectal cancer approval from FDA The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.
News MSD says subcutaneous Keytruda matches IV form A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News FDA looks at Opdivo/Yervoy in first-line colorectal cancer The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
